Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review

Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review

In recent years, precision medicine for non-small cell lung cancer (NSCLC) has made significant strides, particularly with advancements in diagnostic and therapeutic technologies. Targeted 7therapies and Anti-PD-(L)1 Therapies have emerged as vital treatment options, yet KRAS mutations, especially K...

Full description

Saved in:
Bibliographic Details
Main Authors: Fan Zhang, Banglu Wang, Menghuan Wu, Liwen Zhang, Mei Ji
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer (NSCLC)
targeted therapies
KRAS G12C inhibitors
anti-PD-(L)1 therapies
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1509173/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items